1, 25-dihydroxyvitamin D3, a potential role player in the development of thyroid disorders in schizophrenics

Malik, Arif Ali and Saleem, Shamaila and Ashraf, Muhammad Abdul Basit and Qazi, Mahmood Husain (2016) 1, 25-dihydroxyvitamin D3, a potential role player in the development of thyroid disorders in schizophrenics. Pakistan Journal of Medical Sciences, 32 (6). ISSN 1681-715X

[thumbnail of 11157-51882-1-PB.pdf] Text
11157-51882-1-PB.pdf - Published Version

Download (551kB)

Abstract

Objective: The present study was designed to assess the role of vitamin-D, in the development of autoimmune thyroid dysfunction in newly diagnosed schizophrenics.

Methods: For the present study 100 patients and 100 controls were screened out and studied for their thyroid antibodies, GSH, homocysteine, NOS and vitamin D levels by appropriate protocols to assess the underlying mechanism involved in the schizophrenics susceptible to autoimmune thyroid diseases.

Results: The results of the present study depicted that in schizophrenics, levels of cytokines like IL-6 (7.98±0.67 pg/ml), TNF-α, (40.76±6.98 pg/ml), homocysteine (16.98±1.09 µmol/L), Tg-Ab (30.93±3.87 IU/L), TPO-Ab (10.33±1.78 IU/L) and TSHr-Ab (3.76±0.055 IU/L) increased whereas, those of Vit-D (12.76±0.99 pmol/L), NOS (5.99±0.87 IU/L), GSH (4.48±.965 µg/dl) and NO (16.87±3.98 ng/ml) were decreased in the patients as compared to healthy control subjects.

Conclusion: Vitamin-D in schizophrenia is involved in augmentation of hyperhomocysteinemia, inflammation, oxidative stress and thyroid antibodies, thereby playing a significant role not only in induction of schizophrenic symptoms but may also result in autoimmune thyroid diseases. Thus, earlier detection and rectification of its levels are helpful to limit the miseries of schizophrenia.

Item Type: Article
Subjects: STM Library > Medical Science
Depositing User: Managing Editor
Date Deposited: 04 May 2023 04:59
Last Modified: 13 Jan 2024 04:15
URI: http://open.journal4submit.com/id/eprint/1966

Actions (login required)

View Item
View Item